Compare SID & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | NVAX |
|---|---|---|
| Founded | 1941 | 1987 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2002 | 1996 |
| Metric | SID | NVAX |
|---|---|---|
| Price | $1.28 | $8.03 |
| Analyst Decision | Strong Sell | Hold |
| Analyst Count | 1 | 9 |
| Target Price | $1.40 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 7.6M | 3.7M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $2.38 | N/A |
| Revenue Next Year | $2.49 | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $1.11 | $5.01 |
| 52 Week High | $2.20 | $11.85 |
| Indicator | SID | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 34.64 |
| Support Level | N/A | $8.01 |
| Resistance Level | $1.64 | $8.45 |
| Average True Range (ATR) | 0.06 | 0.55 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 84.21 | 9.93 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.